Advertisement

Topics

Immuno-oncology at ASCO: survival data, combinations and new indications

08:09 EDT 17 May 2018 | PMLIVE

The abstracts reveal heaps of strong contenders in the NSCLC category

Original Article: Immuno-oncology at ASCO: survival data, combinations and new indications

NEXT ARTICLE

More From BioPortfolio on "Immuno-oncology at ASCO: survival data, combinations and new indications"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Gilotrif (afatinib)
GILOTRIF (afatinib) is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L8...